Transformation of indolent lymphomas into diffuse large B-cell lymphoma
A. U. Magomedova,
A. M. Kovrigina,
Ya. K. Mangasarova,
S. K. Kravchenko,
E. E. Nikulina,
T. N. Obukhova,
E. E. Zvonkov https://doi.org/10.35754/0234-5730-2024-69-1-112-120
Abstract
Introduction. Lymphoma from cells of the marginal zone in some cases can manifest itself only at the stage of histological transformation into aggressive lymphomas, including diffuse large B-cell lymphoma (DLBCL).
Aim: to present a clinical observation of lymphoma transformed at the time of diagnosis from marginal zone cells to DLBCL.
Main findings. A case report of relapsed DLBCL in the submandibular area is presented, which was observed for 11 years without treatment. At the time of relapse, a 81×43×88 mm mass in the lower lobe of the right lung with SUV max up to 19.27 was identified. Atypical resection of the lower lobe of the right lung was performed. Based on histology and immunohistochemistry, a diagnosis of DLBCL transformed from marginal zone B-cell lymphoma was established, with PCR confirming the identity of the clone of indolent and aggressive B-cell lymphoma. The patient received R-CHOP plus lenalidomide therapy and achieved complete remission.
About the Authors
A. U. Magomedova
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Aminat U. Magomedova, Dr. Sci. (Med.), Leading Researcher of the Department of Lymphatic Tumors with a hematopoietic stem cell transplantation unit and a day hospital
125167, Moscow
A. M. Kovrigina
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Alla M. Kovrigina, Dr. Sci. (Biol.), Head of the Pathology Department
125167, Moscow
Ya. K. Mangasarova
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Yana K. Mangasarova, Cand. Sci. (Med.), Head of the Department of Chemotherapy of Lymphatic Tumors with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit
125167, Moscow
S. K. Kravchenko
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Sergey K. Kravchenko, Cand. Sci. (Med.), Head of the Department of Chemotherapy of Lymphoproliferative Diseases
125167, Moscow
E. E. Nikulina
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Elena E. Nikulina, Research associate Laboratory of Molecular Hematology
125167, Moscow
T. N. Obukhova
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Tatyana N. Obukhova, Cand. Sci. (Med.), Head of the Karyology Laboratory
125167, Moscow
E. E. Zvonkov
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Evgeny E. Zvonkov, Dr. Sci. (Med.), Head of the Department of Hematology and Chemotherapy of Lymphomas with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit
125167, Moscow
References
1. Campo E., Pileri S.A., Jaffe E.S., et al. Nodal marginal zone lymphoma. WHO classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 263–5.
2. Cook J.R., Isaacson P.G., Chott A. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) WHO Classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 259–62.
3. Piris M.A., Isaacson P.G., Swerdlow S.H., et al. Splenic marginal zone lymphoma. WHO classifi cation of Tumors of Haematopoietic and Lymphoid Tissues. 2017; 223–6.
4. Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classifi cation of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720–48. DOI: 10.1038/s41375-02201620-2.
5. Dungarwalla M., Appiah-Cubi S, Kulkarni S., et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation infl uences response to therapy and prognosis. Br J Haematol. 2008; 143(1): 71–4. DOI: 10.1111/j.1365-2141.2008.07301.x.
6. Conconi A, Franceschetti S, Aprile von Hohenstaufen K., et al. Histologic transformation in marginal zone lymphomas. Ann Oncol. 2015; 26(11): 2329–35. DOI: 10.1093/annonc/mdv368.
7. Berger F., Felman P., Thieblemont C., et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000; 95(6): 1950–6.
8. Du Y, Wang Y, Li Q., et al. Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A populationbased study. Int J Cancer. 2024; 154(6): 969–78. DOI: 10.1002/ijc.34773.
9. Kiesewetter B., Lamm W., Dolak W., et al. Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019; 186: 448–59. DOI: 10.1111/bjh.15953.
10. Maeshima A.M., Taniguchi H., Toyoda K., et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016; 174: 923–31. DOI: 10.1111/bjh.14153.
11. Magomedova A., Kravchenko S., Misyurina A., et al. Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate The Effi cacy of The R-DA-EPOCH-21 And R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With De Novo Diffuse BCell Large Cell Lymphoma With Signs of Poor Prognosis — DLBCL-2015 Protocol. Arch Clin Trials. 2022; 2(3): 1–10. DOI:10.33425/2768-4598.1025.
12. Ghesquieres H., Berger F, Felman P., et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006; 24(33): 5234–41. DOI: 10.1200/JCO.2006.07.5671.
13. Lenglet J., Traulle C., Mounier N., et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as fi rst-line treatment. Leuk Lymphoma. 2014; 55(8): 1854–60. DOI: 10.3109/10428194.2013.861067.
14. Wright G.W., Huang D.W., Phelan J.D., et al. A Probabilistic Classifi cation Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications J. Cancer Cell. 2020; 37(4): 551–68.e14. DOI: 10.1016/j.ccell.2020.03.015.
15. Malecka G., Troen, A., Tierens A., et.al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br. J. Haematol. 2018; 183: 838–42. DOI: 10.1111/bjh.15063.
16. Singh M., Jackson K.J.L., Wang J.J., et al. Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody. Cell. 2020; 180: 878– 94.e19. DOI: 10.1016/j.cell.2020.01.029.
17. Flossbach L., Antoneag E., Buck M., et al. BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int. J. Cancer. 2011; 129: 70–7. DOI: 10.1002/ijc.25663.
18. Vorobyev A.I. Questions of the clone theory of leukemia. Problems of hematology. 1965; 2: 14–22.A. (In Russian).
19. Traverse-Glehen A., Felman P., Callet-Bauchu E., et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology. 2006; 48: 162–73. DOI: 10.1111/j.1365-2559.2005.02309.x.
20. Poddubnaya I.V., Savchenko V.G. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow: Buki Vedi, 2018: 52–7. (In Russian).
21. Leonard J.P, Trneny M., Izutsu K., et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019; 37: 1188–99. DOI: 10.1200/JCO.19.00010.
Review
For citations:
Magomedova A.U., Kovrigina A.M., Mangasarova Ya.K., Kravchenko S.K., Nikulina E.E., Obukhova T.N., Zvonkov E.E. Transformation of indolent lymphomas into diffuse large B-cell lymphoma. Russian journal of hematology and transfusiology. 2024;69(1):112-120. (In Russ.) https://doi.org/10.35754/0234-5730-2024-69-1-112-120
Views:
715
Email this article 
